New hope for advanced breast cancer patients in early drug trial
NCT ID NCT07288359
Summary
This early-stage study is testing a new drug called GVV858, both by itself and combined with standard hormone therapies, for people with advanced breast cancer and other solid tumors. The main goals are to find a safe dose and see how well the body handles the drug. Researchers will also check if the treatment helps slow or shrink tumors in patients whose cancer has progressed after prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Novartis Investigative Site
RECRUITINGKyoto, 6068507, Japan
-
Novartis Investigative Site
RECRUITINGSingapore, 168583, Singapore
-
Novartis Investigative Site
RECRUITINGTaipei, 10002, Taiwan
-
Tennessee Oncology PLLC
RECRUITINGNashville, Tennessee, 37203, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.